Home / Europe / Serbia / Life Sciences & Healthcare

Life Sciences & Healthcare

With over 480 international specialist lawyers across CMS and the support of the Life Sciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your life sciences & healthcare business. We work with and have established long-term relationships with the top 100 life sciences & healthcare companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in major industry associations we help shape the legal frameworks impacting the life sciences & healthcare sector.

We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice and compliance. Equally, when you need life sciences & healthcare specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.


Feed

01/06/2022
CMS Next
What’s next? In a world of ever-ac­cel­er­at­ing change, stay­ing ahead of the curve and know­ing what’s next for your busi­ness or sec­tor is es­sen­tial.At CMS, we see ourselves not only as your leg­al ad­visers but also as your busi­ness part­ners. We work to­geth­er with you to not only re­solve cur­rent is­sues but to an­ti­cip­ate fu­ture chal­lenges and in­nov­ate to meet them.With our latest pub­lic­a­tion, CMS Next, our ex­perts will reg­u­larly of­fer you in­sights in­to and fresh per­spect­ives on a range of is­sues that busi­nesses have to deal with – from ESG agen­das to re­struc­tur­ing after the pan­dem­ic or fa­cing the di­git­al trans­form­a­tion. We will also share with you more about the work that we are do­ing for our cli­ents, help­ing them in­nov­ate, grow and mit­ig­ate risk.To be able to provide you with the best sup­port, we im­merse ourselves in your world to un­der­stand your leg­al needs and chal­lenges. However, it is equally im­port­ant that you know who we are and how we can work with you. So, we in­vite you to meet our ex­perts and catch a glimpse of what is hap­pen­ing in­side CMS.En­joy read­ing this pub­lic­a­tion, which we will up­date reg­u­larly with new con­tent.CMS Ex­ec­ut­ive Team
19/05/2022
Can­nabis law and le­gis­la­tion in Ser­bia
Med­ic­al use The Ser­bi­an Law on Psy­cho­act­ive Con­trolled Sub­stances and re­lated reg­u­la­tions con­sider can­nabis as psy­cho­act­ive con­trolled sub­stance (nar­cot­ic drug). Can­nabis is treated in the same man­ner...
08/04/2022
The Pro­posed Dir­ect­ive on Cor­por­ate Sus­tain­ab­il­ity Due Di­li­gence – a step...
The Pro­posed Dir­ect­ive on Cor­por­ate Sus­tain­ab­il­ity Due Di­li­gence (the “CSDD Pro­pos­al”), pub­lished on 23 Feb­ru­ary 2022, aims to im­pose ob­lig­a­tions on com­pan­ies, their sub­si­di­ar­ies and their value chains...
05/04/2022
Re­cent up­dates to the EPO Guidelines for Ex­am­in­a­tion rel­ev­ant to in­ven­tions...
An amended ver­sion of the EPO Guidelines for Ex­am­in­a­tion entered in­to force on 1 March 2022, su­per­sed­ing the edi­tion of March 2021. Here we re­view the up­dates rel­ev­ant to in­ven­tions in the field of bi­o­tech­no­logy...
01/02/2022
UPC: Is it fi­nally here?
New tem­por­ary pro­vi­sions at the European Pat­ent Of­fice re­lat­ing to the Unit­ary Pat­ent The European Pat­ent Of­fice (EPO) is­sued 3 new no­tices on 19 Janu­ary 2022 about the Unit­ary Pat­ent. They are:...
27/01/2022
Schrems II: Re­ac­tions to the judge­ment and the su­per­vis­ory au­thor­it­ies'...
“Schrems II”: Opin­ions of the su­per­vis­ory au­thor­it­ies on Schrems II and re­com­mend­a­tions on the im­ple­ment­a­tion of the judge­ment in in­ter­na­tion­al data trans­fers On 16 Ju­ly 2020, the Court of Justice...
10/12/2021
Glob­al Life Sci­ences & Health­care Fest­iv­al 2021 – Vir­tu­al – High­lights
The emer­gence of new and sus­tain­able tech­no­lo­gies
01/12/2021
A piece of pat­ent his­tory has been made con­cern­ing pat­entab­il­ity of com­puter...
In March 2021 the En­larged Board of Ap­peal of the European Pat­ent Of­fice answered ques­tions con­cern­ing pat­entab­il­ity of com­puter soft­ware sim­u­la­tions in case G1/19.  A Tech­nic­al Board of Ap­peal has now...
24/11/2021
On the Pulse
Wel­come to CMS ‘On the Pulse’ video/pod­cast series for all Life Sci­ences & Health­care pro­fes­sion­als – leg­al, com­pli­ance, reg­u­lat­ory
10/11/2021
COV­ID and ViCo: The End?
En­larged Board of Ap­peal de­cision G1/21 Back­ground Fol­low­ing an EPO press re­lease on 16 Ju­ly 2021, the En­larged Board of Ap­peal’s (EBA) de­cision on video­con­fer­en­cing (ViCo) was re­leased last week. We...
28/10/2021
Arm­chair in­ven­tions: plaus­ib­il­ity at the EPO
Will it get harder to use post-filed data at the European Pat­ent Of­fice (EPO)? The is­sue of plaus­ib­il­ity has now been form­ally re­ferred to the highest ju­di­cial au­thor­ity at the EPO to cla­ri­fy the cir­cum­stances...
17/09/2021
Vac­cine com­pens­a­tion re­gimes in Ser­bia
1. Are COV­ID-19 vac­cin­a­tions ob­lig­at­ory in your jur­is­dic­tion? Are you ex­pect­ing any le­gis­lat­ive changes to en­able man­dat­ory vac­cines for all or cer­tain people (e.g. health­care pro­fes­sion­als, pub­lic ser­vants...
Comparable